Besides Sanofi deal for nuvaxovid, Novavax has few opportunities to generate additional revenue, which likely means its stock ...

Novavax said on Tuesday that it has entered into a termination and settlement agreement with the UK Health Security Agency ...

led by CEO John Jacobs, declined to comment beyond its filings with the Securities and Exchange Commission and press release. Successfully completing this late-stage trial is vital to Novavax’s ...

It comes at a tricky time for Novavax, with CEO John Jacobs promising in August that the company would “unveil a new and expanded clinical pipeline by the end of this year.” Ahead of this ...

In early pandemic days, Novavax (NASDAQ: NVAX) shares soared as investors bet on the company's ability to bring a coronavirus vaccine to market. But as the biotech fell behind in the race and ...

Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

The company’s CEO, Vlad Tenev, announced the launch of futures trading and index options trading at the HOOD Summit 2024 in Miami, Florida. Novavax Inc. NVAX Novavax’s stock took a hit ...

Novavax Inc.’s stock tumbled 19% early Wednesday after the company said the Food and Drug Administration has placed a clinical hold on its COVID-19-and-flu combination and stand-alone flu ...

In the latest market close, Novavax (NVAX) reached $10.35, with a +1.97% movement compared to the previous day. The stock outperformed the S&P 500, which registered a daily loss of 0.02%.

Novavax said a participant enrolled in a mid-stage study of the combination vaccine last month reported symptoms of motor neuropathy, or damage to the nerve cells that control muscles or movement.

Novavax has been gearing up to launch a phase 3 trial of what may result in an important product: A combined flu and coronavirus vaccine. But the company now faces a roadblock, saying regulators ...